Dagan Ron, Greenberg David, Weber Françoise
Pediatric Infectious Disease Unit, Soroka University Medical Center, POB 151, Beer-Sheva 84101, Israel.
Vaccine. 2005 Oct 25;23(44):5144-8. doi: 10.1016/j.vaccine.2005.06.017.
The persistence of anti-hepatitis A virus antibody concentrations was followed over 3 years in 177 healthy children following primary and booster vaccination with an inactivated hepatitis A vaccine, Avaxim 80 pediatric. Seroconversion rates (post-immunization anti-HAV antibody concentration >or=20 mIU/mL) and geometric mean concentrations (GMC) were estimated for each of three age groups: 18 month--3 years, 4--8 years, and 9--15 years. Only subjects who were initially HAV-seronegative at inclusion (<20 mIU/mL) were analyzed. Follow-up visits at years 1, 2, and 3 involved 177, 149, and 135 children, respectively. A decline in GMCs of about 74% occurred during the first year, from 3,060 to 814 mIU/mL overall, but did not continue during years 2 and 3. All subjects remained seropositive (antibody concentration >or=20 mIU/mL), with overall GMCs of 814, 891, and 924 mIU/mL in years 1--3, respectively. The inactivated hepatitis A study-vaccine resulted in sustained seroprotective antibody concentrations in 100% of these children, without a significant decline in antibiotic concentrations over the 3 years following booster injection, thus demonstrating the long-term protection expected with this vaccine.
在177名健康儿童中，使用灭活甲肝疫苗Avaxim 80儿科剂型进行初次和加强免疫接种后，对其抗甲型肝炎病毒抗体浓度的持久性进行了3年的跟踪研究。对三个年龄组（18个月至3岁、4至8岁、9至15岁）分别估计了血清转化率（免疫接种后抗-HAV抗体浓度≥20 mIU/mL）和几何平均浓度（GMC）。仅分析纳入时最初甲型肝炎病毒血清学阴性（<20 mIU/mL）的受试者。第1年、第2年和第3年的随访分别涉及177名、149名和135名儿童。第一年GMC总体下降约74%，从3060降至814 mIU/mL，但在第2年和第3年没有继续下降。所有受试者均保持血清阳性（抗体浓度≥20 mIU/mL），第1至3年的总体GMC分别为814、891和924 mIU/mL。灭活甲肝研究疫苗在这些儿童中100%产生了持续的血清保护性抗体浓度，加强注射后3年内抗体浓度没有显著下降，从而证明了该疫苗预期的长期保护作用。
